L igand-targeted nanomedicines, particularly those directed to vascular-accessible biomarkers, 1,2 have evolved from fanciful concepts 25 years ago to product concepts now near or in clinical trials. While numerous chemical and biological barriers have been discovered and broached over this time frame, perhaps the single greatest challenge to success of nanomedicine technologies has been their inefficient access to extravascular constituents. In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Serrano et al delineates the unique and complex cell biology surrounding ICAM-1 mediated intracellular (and presumably) transcellular delivery of nanoparticles up to 4.5 μm, and illustrates a close mechanistic similarity to leukocyte endothelial transmigration.
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Many have touted the concept of enhanced permeability and retention as a mechanism for nanoparticle delivery into tumors and inflammatory sites through a purportedly leaky vasculature. 3, 4 Considerable research, particularly studies conducted in subcutaneous mouse tumor models, has demonstrated this effect over the last decade, but the magnitude of the extravascular delivery has depended on high intravascular overdosing of agents, prolonging particle systemic half-life (eg, pegylation), and decreasing particle size. 5 Unfortunately, clinical hope for the enhanced permeability and retention effect has waned with recognition that this mechanism is severely curtailed in nonsubcutaneous tumor mouse models, larger mammalian preclinical models, and humans.
In this paper, Daniel Serrano and Silvia Muro elucidate how nanomedicines can co-opt the ICAM-1 endothelial cell pathway for intravascular and, indirectly, transcellular delivery of nanoparticles. Unlike cell adhesion molecule (CAM) mediated endocytosis via clathrin or caveolae-associated vesicles, ICAM-1 based delivery does not associate with dynamin, a GTPase required for budding. 6 Likewise, the involvement of phosphatidylinositol-3-kinase or phospholipase C, essential elements in macropinocytosis and phagocytosis, are not constituents of the ICAM-1 pathway, which requires protein kinase C. 6 Although the formation of actin stress fibers through Src kinase and Rho-dependent kinase pathways is involved in ICAM-1 mediated transport, 6 development of actin cups or microtubules characteristic of macropinocytosis and phagocytosis is not observed. 7, 8 While the ICAM-1 is associated with platelet endothelial cell adhesion molecule-1, 6 the relationship differs from well-known clathrin-mediated uptake involving E-selectin, 9 P-selectin, 10 or vascular cell adhesion molecule-1 11 or from caveolae-associated turnover of thrombomodulin. 12 Serrano et al show that ICAM-1 nanoparticle intracellular transport requires multivalent expression of targeting ligands, which enables rapid engulfment (ie, 15 minutes) of nanocarriers ranging from 180 nm to 4.5 m. Multivalent ICAM-1 engagement interacts with amiloride sensitive Na/H exchange protein NHE1, 13 which functions as a cytoskeleton adapter through ezrin/radixin/moesin proteins and a-actinin 14 to align actin bundles beneath the ICAM-1 targeted particles. 13 Membrane regions for ICAM-1 nanoparticle internalization were associated with lipid raft components, particularly enriched with cholesterol, sphingomyelin, and ganglioside GM1. Depletion of cholesterol with methyl--cyclodextrin or amiloride inhibition of NHE1 impaired particle engulfment but did not impact particle binding, suggesting the criticality of the lipid environment and NHE1 function for nanoparticle internalization.
Serrano et al surmised involvement of acid sphingomylinase (ASM), an acidic enzyme that hydrolyzes sphingomyelin into ceramide, in processes leading to plasmalemma deformability and cytoskeletal reorganization. They demonstrated the role of ASM in ICAM-1 mediated endocytosis through inhibition with imipramine, by demonstrating marked reductions in transport in ASM 2/2 mouse endothelial cells, and by rescuing the engulfment process in ASM 2/2 cells by co-coating recombinant ASM onto the anti-ICAM nanoparticles, yielding a 147% improvement over wild-type endothelial cell transport. Moreover, this mechanism was validated in vivo through intravenous injection into wild-type, caveolin 2/2 , and ASM 2/2 mice, which further revealed that ICAM-1 mediated transport occurred in all but the ASM knockout animals.
At baseline, Serrano et al localized ASM primarily into the perinuclear compartment and to a lesser extent in vesicles outside this perinuclear area. On binding of the ICAM-1 targeted nanoparticles, ASM associated with the cell periphery at ICAM-1 engulfment, but interestingly not with vascular cell adhesion molecule-1, another biosignature of inflammation, nor with the manose-6-phosphate receptor (M6PR), a clathrin-transport component. Surprisingly, ASM did not coimmunoprecipitate with ICAM-1, as opposed to aactinin and moesin, suggesting iCaM-1 and Nanomedicine Nature's doorway to the extravascular tissue realm Gregory M. Lanza that the enzyme converts sphingomyelin to ceramide only in the proximity of the ICAM-1 plasmalemma. Yet, ceramide reaches and enriches the ICAM-1 site. Serrano et al showed that blockade of ceramide production through imipramine inhibition of ASM reduced nanoparticle engulfment while the addition of exogenous neutral sphingomyelinase reversed this effect. Moreover, inhibition of NHE1 decreased ceramide concentrations, which the authors suggest reflects the local role of H 1 efflux to create an acidic environment to support ASM activity. While imipramine inhibition did not prevent ASM recruitment to carrier binding sites, the formation of actin stress fibers induced by ICAM-1 nanoparticle binding was impaired; suggesting that ICAM-1 dependent cytoskeletal rearrangement temporally follows ASM recruitment. They confirmed this hypothesis by inhibiting protein kinase C, which regulated actin stress fiber formation and blocked nanoparticle uptake, but which did not impact ASM recruitment to ICAM-1 binding sites.
Progress in transcytosis of nanoparticles has been slowly forthcoming for lipoproteins, 15-17 caveolae pathways 5,18-20 and neuropilin-based mechanisms. [21] [22] [23] However, the ICAM-1 research presented by Serrano et al is of particular importance, because targeting this natural transcytotic pathway with multi-valent ICAM-1 nanoparticles offers a high efficiency gateway to extravascular pathological targets, which to date have been beyond reach. Co-opting of this pathway may allow nanomedicines to deliver stabilizing treatments for atherosclerosis, aneurysms, and innumerable inflammatory vasculitidies. While this work focused on pulmonary preclinical models, further research is required to establish whether these mechanisms are ubiquitous across vascular beds or individualized in an organ or pathology dependent manner.
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